Several different sequences are implicated in bloodstream-form-specific gene expression in *Trypanosoma brucei*

Tania Bishola Tshitenge, Lena Reichert, Bin Liu# and Christine Clayton

Heidelberg University Center for Molecular Biology (ZMBH), Heidelberg, Germany

#Current address: Hebei Viroad Biotechnology Co. Ltd, Shijiazhuang, China

Abstract

The parasite *Trypanosoma brucei* grows as bloodstream forms in mammalian hosts, and as procyclic forms in tsetse flies. In trypanosomes, gene expression regulation depends heavily on post-transcriptional mechanisms. Both the RNA-binding protein RBP10 and glycosomal phosphoglycerate kinase PGKC are expressed only in mammalian-infective forms. RBP10 targets procyclic-specific mRNAs for destruction, while PGKC is required for bloodstream-form glycolysis. Developmental regulation of both is essential: expression of either RBP10 or PGKC in procyclic forms inhibits their proliferation. We show that the 3'-untranslated region of the *RBP10* mRNA is extraordinarily long - 7.3kb - and were able to identify six different sequences, scattered across the untranslated region, which can independently cause bloodstream-form-specific expression. The 3'-untranslated region of the *PGKC* mRNA, although much shorter, still contains two different regions, of 125 and 153nt, that independently gave developmental regulation. No short consensus sequences were identified that were enriched either within these regulatory regions, or when compared with other mRNAs with similar regulation, suggesting that more than one regulatory RNA-binding protein is important for repression of mRNAs in procyclic forms. We also identified regions, including an AT repeat, that increased expression in bloodstream forms, or suppressed it in both forms. Trypanosome mRNAs that encode RNA-binding proteins often have extremely extended 3'-untranslated regions. We suggest that one function of this might be to act as a fail-safe mechanism to ensure correct regulation even if mRNA processing or expression of *trans* regulators is defective.

Introduction

Kinetoplastids are unicellular flagellated parasites that infect mammals and plants. The African trypanosome *Trypanosoma brucei* is a kinetoplastid that causes sleeping sickness in humans in Africa and infects livestock throughout the tropics, with a substantial economic impact [1]. *T. brucei* are transmitted by a definitive host, the Tsetse fly, or during passive blood transfer by biting flies. The parasites multiply extracellularly as long slender bloodstream forms in the mammalian blood and tissue fluids, escaping the host immune response by expressing different Variant Surface Glycoproteins (VSGs) [2]. High cell density triggers growth arrest and a quorum sensing response, prompting differentiation of the long slender bloodstream forms to stumpy forms [3]. The stumpy form is pre-adapted for differentiation into the procyclic form, which multiplies in the Tsetse midgut. The transition from the mammalian host to the Tsetse fly entails a decrease in temperature, from 37°C to between 20°C and 32°C; and a switch from glucose to amino acids as the main source of energy, with a concomitant change to dependence on mitochondrial metabolism for energy generation [4, 5]. Meanwhile, the VSG coat is replaced by the procyclins [6, 7]. Procyclic forms later undergo further differentiation steps before developing into epimastigotes, and then mammalian-infective metacyclic forms in the salivary glands [8]. The developmental transitions in the *T. brucei* life cycle are marked by extensive changes in mRNA and protein levels [9-17]. Differentiation of trypanosomes from the bloodstream form to the procyclic form can be achieved *in vitro* through addition of 6 mM cis-aconitate and a temperature switch from 37°C to 27°C, followed by a medium change [18, 19].

Bloodstream-form trypanosomes rely on substrate-level phosphorylation for ATP generation, and the first seven enzymes of glycolysis and glycerol metabolism are located in a microbody, the glycosome [20, 21]. Within the branch of the pathway that has pyruvate as the end-product, the last enzyme that is in the glycosome is phosphoglycerate kinase (PGK). In procyclic-form trypanosomes, although the glycosomal glycolytic pathway is retained, it has some other roles and most phosphoglycerate kinase activity is in the cytosol. The trypanosome genome encodes three PGK isozymes [22], all of which are enzymatically active [23-25]. PGKA is expressed at low levels and is in the glycosome [26]; PGKB is the cytosolic enzyme found in procyclic forms; and PGKC is the glycosomal isozyme that is found in mammalian-infective forms [27, 28]. This regulated compartmentation is essential. Expression of cytosolic PGK is lethal to bloodstream-form trypanosomes [29], perhaps because it disrupts the ATP/ADP balance within the glycosome [30, 31]; and expression of PGKC in procyclic forms is similarly lethal (at least in the presence of glucose), probably because it reduces cytosolic ATP production [32].

In Kinetoplastids, nearly all protein-coding genes are arranged in polycistronic transcription units. Mature mRNAs are generated from the primary transcript by 5'-*trans*-splicing of a 39nt capped leader sequence, and by 3'-polyadenylation (reviewed in [33, 34]). The detection of intergenic RNA from the *PGK* locus was indeed one of the early pieces of evidence for polycistronic transcription [35]. Polyadenylation is not very precise: sites are found in a region that is about 140nt upstream of the *trans*-splice site that is used to process the following mRNA [11, 36], and quite often, alternative splice acceptor sites (and therefore

polyadenylation sites) are used. The parasite regulates mRNAs mainly by post-transcriptional mechanisms, supplemented, in the case of some constitutively abundant mRNAs, by the presence of multiple gene copies. Regulation of mRNA processing, degradation, and translation are therefore central to parasite homeostasis, and for changes in gene expression during differentiation [14-17]. The sequences required for regulation of mRNA stability and translation often lie in the 3'-UTRs of the mRNAs, and most regulation so far has been found to depend on RNA-binding proteins [37, 38].

RBP10 (Tb927.8.2780) is an RNA-binding protein which has been detected only in bloodstream forms and metacyclic forms. The *RBP10* mRNA is also much more abundant in bloodstream forms than in procyclic forms [9, 10, 39-41]; it persists in stumpy forms [42-44], but decreases rapidly after induction of differentiation [45]. Within the Tsetse fly, *RBP10* mRNA may be up-regulated in metacyclic forms [9, 10, 46] although this was not seen in all studies. Procyclic forms can be induced to differentiate to epimastigotes, and then mammalian-infective metacyclic forms, by induced expression of the RNA-binding protein RBP6 [46, 47]. RBP10 protein is detected in bloodstream forms [39] and RBP6-induced metacyclic forms [40, 47]. Using mass spectrometry, the degree of RBP10 regulation is difficult to calculate because of poor detectability in procyclic forms, but was estimated in one study at 25-fold [48]; in another, RBP10 protein was undetectable in stumpy forms [13]. RBP10 specifically associates with procyclic-specific mRNAs that contain the motif UA(U)₆ in their 3'-UTRs, targeting them for destruction [49]. Depletion of RBP10 from bloodstream forms gives cells that can only grow as procyclic forms [49] and RBP10 expression in procyclic forms makes them able to grow only as bloodstream forms, with expression of some metacyclic-form *VSG* mRNAs but no detectable formation of epimastigotes [49, 50]. After RBP6 induction in procyclic forms, RBP10 was also required for expression of metacyclic *VSG* mRNAs [46]. Correct developmental regulation of RBP10 is therefore critical throughout the parasite life cycle.

The distribution of 3'-UTR lengths in trypanosomes is remarkably broad. Initial estimates from high-throughput RNA sequencing (RNA-Seq) suggested median lengths of 400-500nt [11, 36] and 6% over 2kb. Subsequent studies of individual genes have revealed that these are under-estimates: some trypanosome mRNAs have 3'-UTRs of 5kb or more. This is rather unusual compared with Opisthokont model organisms. For example, *Saccharomyces cerevisiae* 3'-UTRs are 0-1461nt long, with a median of 104nt [51], while *Caenorhabditis elegans* 3'-UTRs have a median length of 133nt; less than 2% of *C. elegans* mRNAs had 3'-UTRs longer than 2kb [52]. Interestingly, the longest trypanosome 3'-UTRs tend to be found in mRNAs encoding RNA-binding proteins and protein kinases [37]. Since these protein classes have vital regulatory functions, it is likely that their expression has to be particularly tightly controlled. For example, the mRNA encoding the procyclic-specific mRNA binding proteins ZC3H22 has a 3'-UTR that is over 5kb long, with 9 copies of the UA(U)₆ motif [53].

Over 400 *T. brucei* mRNAs are at least 10-fold better expressed in bloodstream forms than in procyclic forms (as judged by ribosome footprints) [14]. To our knowledge, however the only short RNA motif that has so far been implicated in such regulation is an 8mer that is specific to the 3'-UTR of the *VSG* mRNA

[54]. In a previous study, we used a reporter assay to examine the functions of various segments of the *PGKC* 3'-UTR [55]. Results from deletions indicated that the sequences that were required for developmental regulation were in the terminal 424nt of the *PGKC* 3'-UTR [55] - a region that is likely to be bound by several different proteins [56]. In this paper, we aimed to find shorter sequences that are responsible for the bloodstream-form-specific expression of both the *PGKC* and *RBP10* mRNAs. We found that *PGKC* has at least two such sequences, while *RBP10* has at least four which are scattered throughout the 7.2 kb 3'-UTR. Our results suggest that several different sequence motifs - and therefore, probably, a similar number of RNA-binding proteins - are implicated in controlling bloodstream-form-specific mRNA stability and translation.

Materials and methods

Trypanosome culture

The experiments in this study were carried out using the pleomorphic cell line EATRO 1125 [57], constitutively expressing the tetracycline repressor. The bloodstream form parasites were cultured as routinely in HMI-9 medium supplemented with 10% heat inactivated foetal bovine serum at 37°C with 5% CO₂. During proliferation, the cells were diluted to 1x10⁵ cells/ml and maintained in density between 0.2-1.5x10⁶ [58]. To preserve the pleomorphic morphology between the experiments, the EATRO 1125 cells were maintained in HMI-9 medium containing 1.1% methylcellulose [59]. For generation of stable cell lines, ~1-2 x 10⁷ cells were transfected by electroporation with 10 µg of linearized plasmid at 1.5 kV on an AMAXA Nucleofector. Selection of newly transfectants was done after addition of appropriate antibiotic and serial dilution. The differentiation of bloodstream forms to procyclic forms was induced by addition of 6mM *cis*-aconitate (Sigma) to 1x10⁶ long slender trypanosomes; after 17-24h, the cells were transferred into procyclic form media (~ 8x10⁵ cells/ml) and maintained at 27°C without CO₂.

Plasmid constructs

To assess the role of the *RBP10* 3'-UTR at full length, a cell line expressing a chloramphenicol acetyltransferase (*CAT*) mRNA with the *RBP10* 3'-UTR was generated by replacing one allele of the *RBP10* coding sequence with the coding region of the *CAT* reporter. The *RBP10* 5'-UTR was also replaced with the beta-tubulin (*TUB*) 5'-UTR (Figure 1E). To map the regulatory sequences, plasmids used for stable transfection were based on pH2164, a dicistronic vector containing the *CAT* and neomycin phosphotransferase (*NPT*) resistance genes (Figure 2A). Downstream of the *CAT* gene we cloned different fragments of the *RBP10* 3'-UTR in place of the actin (*ACT*) 3'-UTR, using *Sa*I and *Xho*I restriction sites (Figure 2A). The different fragments were obtained by PCR using genomic DNA from Lister 427 trypanosomes as the template. Mutations on smaller fragments of the *RBP10* 3'-UTR were done using either site directed mutagenesis (NEB, Q5® Site-Directed Mutagenesis Kit Quick Protocol, E0554) or by PCR mutagenesis with Q5 DNA polymerase.

To study the *PGKC* 3'-UTR, the starting plasmid used, pH3261 (Figure 3A), was built by incorporating various fragments either from previous plasmids [54], or made by PCR amplification with plasmid templates. The starting plasmid contains 790nt of the *PGKC* 3'-UTR, re-amplified from [60]. Most of the sequence, apart from the plasmid backbone, was verified by sequencing and is included as Supplementary text S2. Deletions were done by specific PCR followed by cloning between the *Bam* HI and *Sal* I sites (Figure 3). Some deletions occurred during the PCR, so the 3'-UTR sequences used are included as supplementary Figure S1. The reconstructed sequence of the derivative with the 3'-UTR of genes encoding actin (*ACT*) is Supplementary File S2.

The precise details of the different constructs and their associated primers used for cloning are included in Supplementary table S1.

RNA analysis

Total RNA was isolated from approximately 1×10^8 bloodstream-form trypanosomes or 5×10^7 procyclic-form cells growing in logarithmic phase (less than about 8×10^5 /ml for bloodstream forms, or 4×10^6 /ml for procyclic forms) using either peqGold Trifast (PeqLab) or RNAzol RT following the manufacturer's instructions.

To detect the *CAT* or *GFP* mRNAs by Northern blot, 5 or 10 µg of total RNA was resolved on formaldehyde agarose gels, transferred onto nylon membranes (GE Healthcare) by capillary blotting and fixed by UV-crosslinking. The membranes were pre-hybridized in 5x SSC, 0.5 % SDS with 200 mg/ml of salmon sperm DNA (200 mg/ml) and 1x Denhardt's solution, for an hour at 65°C. The probes were generated by PCR of the coding sequences of the targeted mRNAs, followed by incorporation of radiolabelled [α^{32} P]-dCTP and purification using the QIAGEN nucleotide removal kit according to the manufacturer's instructions. The purified probes were then added to the prehybridization solution and the membranes were hybridized with the respective probes at 65°C for overnight (while rotating). After rinsing the membranes in 2x SSC buffer/0.5% SDS twice for 15 minutes, the probes were washed out once with 1x SSC buffer/0.5% SDS at 65°C for 15 minutes and twice in 0.1x SSC buffer/0.5% SDS at 65°C each for 10 minutes. The blots were then exposed onto autoradiography films for 24-48 hours and the signals were detected with the phosphorimager (Fuji, FLA-7000, GE Healthcare). Care was taken to ensure that signals were not over-exposed so that quantitation would be in the linear range. The signal intensities of the bands were measured using ImageJ. *CFP* mRNA levels were measured by quantitative real-time PCR as previously described [61].

To measure mRNA half-lives mRNA transcription and *trans*-splicing were simultaneously inhibited by addition to the growth culture medium of 10 µg/ml Actinomycin D and 2 µg/ml Sinefungin. The cells were collected at the indicated different time points and RNA was isolated by Trizol extraction [62]. The mRNA levels were assessed by Northern blotting.

CAT Assay

To perform the CAT assays, approximately 2×10^7 cells were harvested at 2300 rpm for 8 minutes and washed three times with cold PBS. The pellet was re-suspended in 200 μ l of CAT buffer (100mM Tris-HCl pH 7.8) and lysed by freeze-thawing three times using liquid nitrogen and a 37°C heating block. The supernatants were then collected by centrifugation at 15,000 $\times$ g for 5 min and kept in ice. The protein concentrations were determined by Bradford assay (BioRad) according to the manufacturer's protocol. For each setup, 0.5 μ g of protein in 50 μ l of CAT buffer, 10 μ l of radioactive butyryl CoA (14 C), 2 μ l of chloramphenicol (stock: 40 mg/ml), 200 μ l of CAT buffer and 4 ml of scintillation cocktail were mixed in a Wheaton scintillation tube HDPE (neoLab #9-0149) and the incorporation of radioactive acetyl group on chloramphenicol was measured using a Beckman LS 6000IC scintillation counter.

Western blots

Protein samples were collected from approximately 5×10^6 cells growing at logarithmic phase. Samples were run according to standard protein separation procedures using SDS-PAGE. The primary antibodies used in this study were mouse monoclonal IgG (Santa Cruz Biotechnology) and rat α -ribosomal protein S9 (own antibody). We used horseradish peroxidase coupled secondary antibodies (α -rat, 1:2000 and α -mouse, 1:1000). The blots were developed using an enhanced chemiluminescence kit (Amersham) according to the manufacturer's instructions. The signal intensities of the images were quantified using ImageJ. The raw data are shown in Supplementary Figure S2.

Results

The *RBP10* 3'-UTR is sufficient for developmental regulation

Our first experiments were designed to check high-throughput results concerning RBP10 regulation. Results from RNA-Seq and ribosome profiling [17] suggest that the 3'-UTR is about 7.3 kb long, giving a total mRNA length of about 8.5 kb (Figure 1A). The middle region of the 3'-UTR is present in one other contiguous sequence in the TREU927 genome assembly (giving the grey-coloured reads in the alignment in Figure 1A) but this sequence is found only once in the Lister 427 strain genome [63]. In our experiments we used the EATRO1125 *T. brucei* strain, which is differentiation-competent but for which an assembled genome is not yet publicly available. The gene immediately downstream of *RBP10* (Tb927.8.2790) is annotated as an acetyl-coA synthetase pseudogene. A complete acetyl-coA synthetase coding region is present elsewhere in the genome, but the presence of read alignments over the region that surrounds the Tb927.8.2790 coding region suggests that the pseudogene mRNA is also present in both bloodstream and procyclic forms.

Previous transcriptome and ribosome profiling results indicated that there are about 4 copies of *RBP10* mRNA per cell in bloodstream forms, and slightly under 1 per cell in procyclic forms [15], but that the ribosome density on the coding region is 9 [16] or 100 [14] times higher in bloodstream forms. Northern blot results for the EATRO1125 strain showed an *RBP10* mRNA that migrated slower than the 6kb marker (Figure 1B). Extrapolation suggested a length of about 8.5 kb. In this experiment, there was 8-fold more

RBP10 mRNA in bloodstream forms than in procyclic forms (Figure 1B). The amount of RBP10 protein decreased about 3-fold after 24h incubation with 6mM *cis*-aconitate at either 20°C or 27°C, and both *cis*-aconitate and the temperature drop were required for the regulation (Figure 1C). Previous RNA-Seq measurements suggested an *RBP10* mRNA half-life of just over 1h in Lister 427 bloodstream forms [15]. Three new individual measurements in EATRO1125 were difficult to interpret because of an initial apparent increase in the mRNA, but did suggest a half-life of 1-2 h (Figure 1D). The initial increase has previously been seen for other stable mRNAs and its cause is unknown. For procyclic forms, the RNA-Seq replicates for degradation measurements were very poor [15], but from Northern blotting the half-life was probably less than 30 min (Figure 1D).

Finally, to find out whether the *RBP10* 3'-UTR was sufficient for regulation, we integrated a chloramphenicol acetyltransferase (*CAT*) gene into the genome of strain EATRO1125 bloodstream forms, directly replacing one *RBP10* allele (Figure 1E). After differentiation to procyclic forms, *CAT* mRNA was about 3-fold down-regulated, but there was no detectable *CAT* activity (Figure 1E). This shows that the *RBP10* 3'-UTR is sufficient for developmental regulation.

The *RBP10* 3'-UTR contains numerous regulatory elements

In order find sequences that contribute to the stability and translation of *RBP10* mRNA in bloodstream forms, or to its instability and translational repression in procyclic forms, we made use of a reporter plasmid that integrates into the tubulin locus, resulting in read-through transcription by RNA polymerase II. The *CAT* reporter mRNA has a 5'-UTR and splice signal from an *EP* procyclin gene (Figure 2A). At the 3'-end between *CAT* and *NPT* is an intergenic region from between the two actin genes, with a restriction site exactly at the mapped polyadenylation site (Figure 2A). Polyadenylation of the *CAT* mRNA is directed by the polypyrimidine tract that precedes the *ACT* 5'-UTR. Cell lines can be selected with G418 using the *NPT* (neomycin phosphotransferase) marker, the mRNA of which has an *ACT* 5'-UTR. The reporter produces a *CAT* mRNA bearing the *ACT* 3'-UTR, with polyadenylation driven by the downstream splice site for *NPT*. In all experiments, the reporter plasmid was transfected into EATRO1125 bloodstream forms and two or three independent clones were then differentiated into procyclic forms. *CAT* activities were measured enzymatically and mRNA levels were measured by Northern blotting, which simultaneously allowed us to check the sizes of the mRNAs. All values were normalised to arithmetic mean results from the *ACT* 3'-UTR control. The sizes of the mRNAs are tabulated in Supplementary Table S2 and the sequences are in Supplementary text 1. Most of the reporter mRNAs migrated either as expected, or slightly faster. The latter suggests polyadenylation upstream of the expected sites.

First, we examined four different fragments (1-4 in Figure 2B), each roughly 2 kb long. Fragment 4 extends beyond the *RBP10* polyadenylation site, including the intergenic region before downstream gene (Tb927.8.2790); and the size of the resulting RNA suggested use of the genomic processing signals (Supplementary Table S2). It was notable that the results for RNA were much more variable than for the *CAT* activity. Since RBP10 protein also shows more regulation than the RNA, the following discussion will

consider mostly the CAT activity. We consider CAT activity to be "low" ("-" in Figure 2) if the median value was less than 25% of the activity measured using our standard, the 3'-UTR from an actin gene (*ACT*), and "high" ("++" in Figure 2) if the median CAT activity was more than twice the control; results in between are designated "+". The degree of developmental regulation is calculated by dividing the lowest value for bloodstream forms by the highest value in procyclic forms. We did not calculate P-values because the distributions of the measurements were mostly not normal, and here discuss only the fragments that gave similar results for all replicates. To our surprise, all of the 2kb fragments gave low CAT activity in procyclic forms (Figure 2B). Fragment 2 also reproducibly gave high CAT activity in bloodstream forms (Figure 2B). Clearly, several regulatory sequences were present. We next further dissected the fragments. We attempted to examine sequences of equal sizes, but were constrained by the need to design PCR primers that avoided the numerous low-complexity sequences in the *RBP10* 3'-UTR. Our results showed that fragments 1.1, 1.2, 1.4 and 2.2.2 (Figure 2B) each gave low CAT activity in procyclic forms with at least 4-fold developmental regulation; 1.2 also reproducibly gave more activity in bloodstream forms than the parent sequence. Fragment 1.4 (234nt) was the shortest that gave this pattern; when it was cut in half, regulation was lost, either because we accidentally cut within a relevant motif, or because the cleavage adversely affected a required secondary structure. Fragments 3.2 and 3.2.2 gave low CAT activity in both stages although the mRNA was readily detected, suggesting possible translation repression. Fragments 2.1 and 2.2.4 suppressed CAT activity in procyclics but with rather low CAT activity in bloodstream forms and little RNA regulation, suggesting a role in repression of translation in procyclic forms.

It was notable that sometimes, fragmentation of a sequence revealed activity that had been absent previously: for example, fragment 2.2 gave no regulation but the sub-fragment 2.2.2 regulated like fragment 2. Fragment 2.2 may also include a repressive element whose removal results in high activity in bloodstream forms (fragment 2.2.3). Fragment 3.1 also gave high activity in bloodstream forms. (Figure 2B). These results show that regulation of RBP10 expression is achieved by numerous sequence elements.

At least two segments of the *PGKC* 3'-UTR contain regulatory elements.

For *PGKC*, we used the reporter plasmid shown in Figure 3A. After restriction enzyme cleavage and transfection, the plasmid integrates into the tandemly repeated alpha-beta tubulin array, cleanly replacing an alpha tubulin gene (Figure 3A). It is therefore, like the previous reporter, transcribed by RNA polymerase II. A cyan fluorescent protein (*CFP*) reporter open reading frame is followed by a 3'-UTR, then an intergenic region (IGR), splice signal and 5'-UTR from the actin (*ACT*) locus. Splicing of the mRNA encoding CFP is directed by the alpha-tubulin signal, resulting in a *CFP* mRNA with an alpha-tubulin 5'-UTR and the 3'-UTR of interest - in this case, the ~780nt 3'-UTR of *PGKC*. The puromycin resistance marker mRNA (*PAC*, puromycin acetyltransferase) is trans-spliced using the signal from the *ACT* gene. This splice signal also directs polyadenylation of the *CFP* reporter mRNA, approximately at the position of the *Sa*/I site that divides the tested 3'-UTRs from the intergenic region (Figure 3A). A full sequence of the plasmid is included as Supplementary text 1. To design deletions (Figure 3B) we examined the predicted secondary structure of

the 3'-UTR using the RNAfold web server (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>). The resulting predictions are not included here because they were not subsequently verified in any way. However, our deletions were designed to avoid disruption of putative secondary structure. The full sequence is in Supplementary text S2. For each deletion, several plasmids were sequenced and the one that best matched the expected sequence was selected for further use. In some cases a few nucleotides were deleted or exchanged: an alignment that shows all of the 3'-UTR sequences tested is in Supplementary Figure S1. (Plasmids 17 and 18 are not included but had no mutations relative to plasmid 16.)

To test the functions of the 3'-UTR segments, we cut each plasmid to remove the plasmid backbone, transfected the DNA into bloodstream-form trypanosomes, and selected independent populations for further analysis. The transfection should normally result in parasites with a single copy of the plasmid into the alpha-beta-tubulin tandem repeat, although insertion of two or more copies would be possible. To allow for this, two different populations for each plasmid were selected for protein preparation, RNA preparation, and differentiation into procyclic forms. Protein levels were assessed for each population by quantitative Western blotting, with ribosomal protein S9 as a loading control (Figure 3C). RNA levels were measured in triplicate technical replicates for each clone, by reverse transcription and real-time PCR (Figure 3D). All values were normalized to the average of expression in bloodstream forms for the 782nt full-length *PGKC* 3'-UTR. The lengths of the mRNAs, measured in bloodstream forms (Figure 3E) mostly appeared to be around 100nt longer than the expected lengths, which were calculated assuming a poly(A) tail length of 60nt (Supplementary Table S2). Either we under-estimated the poly(A) tail length, or the Northern measurements are consistently a little too long.

Our results revealed that all fragments that included the final 278nt showed developmental regulation of protein levels: the amount of protein in procyclic forms was too low to measure accurately (Fragments 1-5; Figure 3C). For these 3'-UTR fragments, RNA in procyclic forms was 15%±6% of the bloodstream-form level. The difference in mRNA level was less than that seen previously seen using *CAT*, and also less than that seen with the mRNAs that include the *PGK* coding region. It was also rather more variable, as we had previously observed for RBP10 (Figure 3D). Perhaps the mRNA level is more sensitive to cell density than the protein level; and the coding region may also contribute [64, 65]. We here therefore focus mainly on regulation of protein expression. Bloodstream-form levels of expression for fragments 4 and 5 were slightly lower than for the full-length plasmid but probably within the error of the method (Figure 3C). Next, we deleted from the 3'-end (Figure 3B, fragments 6-9). Deletion of the final 278nt (Figure 3B, fragment 7) was sufficient to abolish developmental regulation (Figure 3C). Intriguingly, further deletion (Fragment 8) gave a plasmid which again showed a roughly 2-fold difference between bloodstream and procyclic forms, while an additional deletion (Fragment 9) resulted in no regulation.

The results so far localized the regulatory sequences to the last 278 nt of the 3'-UTR. Testing of individual fragments, however, gave a more nuanced picture. Fragment 12 gave regulation like fragment 8. Fragment

13 contains a UA(U)₆ motif, but fragment 13, if anything, gave slightly more expression in bloodstream forms than in procyclic forms. Fragments 14 and 15 independently suppressed expression in procyclic forms, indicating that they contain two separate regulatory elements, although fragment 15 was the most effective. Fragment 16 - which includes fragments 13 and 14 - behaved like fragment 14. We next made 3'- deletions of fragment 16. Intriguingly, an initial truncation (fragment 17) gave a 3'-UTR with no regulation at all, but further removal (plasmid 18) restored the regulation. Plasmid 18 contains just 61nt of fragment 14 (designated with an asterisk). The combined results suggest that the 61nt in plasmid 18 include a region that represses expression in procyclic forms, but whose function is affected by the surrounding sequence. Additional regulatory elements are in fragments 12 and 15.

AU-Rich elements affect expression

We next looked for regulatory motifs that could be tested in another sequence context. First, we searched for sequences that might specifically repress expression in procyclic forms. We compared different sets of sequences using MEME or DREME [66, 67]. We initially searched for 6-12 nt motifs enriched in the *RBP10* regulatory fragments relative to the those that lacked regulation. (The maximum was set because most RNA-binding proteins are specific for less than 12nt.) No motifs were found but the sample size was small, so we expanded the dataset by including 3'-UTRs from other co-regulated bloodstream-form specific mRNAs: the two regulatory regions for *PGKC*, Phosphofructokinase (Tb927.3.3270), pyruvate kinase (Tb927.10.14140), glycerophosphate isomerase (Tb927.1.3830, the hexose transporter THT1 (Tb927.10.8450) [68], and an aquaglyceroporin (Tb927.10.14160) - 11 sequences altogether. As a comparator we used 402 3'-UTRs from procyclic-specific mRNAs, of the same average length. No motifs with statistically significant enrichment were found in the bloodstream-form mRNAs.

Next, we looked at low-complexity regions which might serve to bind multiple copies of sequence-specific RNA-binding proteins. One element consists of (AU) repeats, present in fragments 1.2 ((AU)₁₁), 1.3 ((AU)₉ and (AU)₈), and 3.2.1 ((AU)₁₀), and of course the larger fragments that include them. We had some previous preliminary data that suggested that this sequence was implicated in good expression of ZC3H11, so we tested its function in the context of the *RBP10* 3'-UTR. Deletion of the AU repeat from *RBP10* fragment 1.2 indeed resulted in a drastic decrease of reporter expression levels (Figure 4A). Further, several fragments of the *RBP10* 3'-UTR contain poly(A) tracts (F1.2, 2.1, 2.2.1, 2.2.2, 2.2.3, 3.1.2 and 3.2.1), and we speculated that they might act by recruiting a poly(A) binding protein. However, deletion of the poly(A) tracts from one of these fragments unexpectedly resulted in an increase in reporter expression levels, rather than a decrease (Figure 4B).

To find out whether either the (AU)-rich element could enhance expression in another context, we inserted it between the *CFP* coding region and the *ACT* 3'-UTR. There was no effect on expression (Figure 4C). Similarly, the 61nt fragment from the *PGKC* 3'-UTR (PGK*) could also not regulate upstream of the *ACT* 3'-UTR. In both cases, therefore, the functions of these sequences depend on the surrounding sequence context.

Discussion

The main aim of this study was to find sequences that can cause bloodstream-form specific expression in *T. brucei*, while a secondary aim was to investigate the general reason for the existence of very long 3'-UTRs. Regarding the first aim, we found that the *RBP10* 3'-UTR contains at least six sequences that specifically give low expression in procyclic forms (fragments 1.1, 1.2, 1.4, 2.2.2, 3 and 4) while the much shorter *PGKC* 3'-UTR contains at least two. There was also evidence, from the *RBP10* 3'-UTR, for sequences that stimulate expression in bloodstream forms (1.1, 1.2, 2.2.3, 3.1), or repress (3.2.2) or enhance (2.2.3) in both forms. We were unable to identify any specific short (<12nt) enriched motifs, either repeated within the *PGKC* and *RBP10* 3'-UTRs, or in comparison with other similarly regulated mRNAs. However, we were able to narrow down the regulatory regions considerably. The absence of a single enriched motif suggests that several different *trans*-acting factors, with different sequence specificities, are able to act independently to ensure appropriate expression of both *PGKC* and *RBP10* (Figure 5). These factors probably each act on a subset of other similarly regulated mRNAs as well. Therefore, if our results are combined with further investigations of additional 3'-UTRs, it is likely that some short regulatory motifs will begin to emerge. Our results also suggested that the action of the regulatory motifs is context-dependent. For example, fragment 2.2.2 gave stronger regulation than the parent fragment 2.2, and fragment 3.1 gave higher activity in bloodstream forms than fragment 3 (Figure 2B). Perhaps the different fragments are bound by proteins that compete for binding on the *RBP10* 3'-UTR and this binding is influenced by secondary structures. Therefore, a dissection might allow some proteins to bind more efficiently while others are losing binding.

Many studies of mRNA binding proteins compare the mRNAs that are bound to that protein with the effects on the transcriptome after depletion of that protein. It is notable that in most cases, some bound mRNAs show clear changes in abundance after the protein is depleted, whereas others are unaffected. Our results clearly show why this is the case: for at least some mRNAs, regulation can be sustained by more than one region of the mRNA and probably, more than one RNA-binding protein. In practical terms, our results mean that screens for RNA-binding proteins that regulate one specific mRNA are unlikely to succeed if the reporter that contains the whole 3'-UTR is used for selection. For example, elimination of the regulatory protein that binds to fragment 15 of the *PGKC* 3'-UTR would probably have no effect on *PGKC* expression because regulation could be maintained by the sequences in fragment 14 (Figure 5). Indeed, a screen that was designed to find *trans* acting factors that regulate the mRNA encoding glycosyl phosphatidylinositol phospholipase C resulted only in the selection of 3' deletion mutants [69]. In order to search for proteins that regulate *PGKC* and *RBP10* expression, it will probably be necessary to focus on the individual regulatory segments. Once such proteins are identified it is likely that they will be found to regulate other bloodstream-form-specific mRNAs as well.

The 3'-UTRs of the *RBP10* mRNA, and many other mRNAs encoding RNA-binding proteins, are extraordinarily long. Khong and Parker [56] have calculated that Opisthokont mRNAs are probably bound

by at least 4-18 proteins/kb. If trypanosomes are similar, the *RBP10* 3'-UTR would be predicted to bind 28-126 proteins, while the *PGKC* 3'-UTR would bind between 3 and 14. Long mRNAs generally have relatively low abundances [15], which might be important for regulatory proteins. The results presented here, however, suggest that long 3'-UTRs may have evolved as a "fail-safe" mechanism that ensures correct regulation even if the 3'-UTR is truncated by alternative processing, or one of the controlling proteins is absent.

Data availability

The Northern blots for the RBP10 experiments can be found at https://figshare.com/articles/figure/Northern_blot_RBP10_3'_UTR/17085989

Author contributions

Tania Bishola was responsible for nearly all of the experimental work with *RBP10*, provided figures and tables, wrote the first draft of the paper and was involved in subsequent editing. Dr. Bin Liu supervised in the initial phase of the *RBP10* study. Lena Reichert and Christine Clayton did the work on *PGKC*. Christine Clayton devised and supervised the project, edited the paper and provided funding.

Acknowledgments

We thank Dr. Monica Terrao for some initial analysis of the *RBP10* 3'-UTR. Six fragments of the *RBP10* 3'-UTR were cloned by Juyeop Kim, a master student, during his 6-week lab rotation. We thank Claudia Helbig and Ute Leibfried for technical assistance, for preparing media and buffers. We are indebted to Prof. Dr. Nina Papavasiliou (DKFZ, University of Heidelberg) and Prof. Dr. Luise Krauth-Siegel (BZH, University of Heidelberg) for allowing us to share their laboratories including equipment and reagents after the flood in ZMBH.

References

- Shaw AP, Cecchi G, Wint GR, Mattioli RC, Robinson TP. Mapping the economic benefits to livestock keepers from intervening against bovine trypanosomosis in Eastern Africa. *Prev Vet Med.* 2014;113(2):197-210. Epub 2013/11/28. doi: 10.1016/j.prevetmed.2013.10.024. PubMed PMID: 24275205.
- Gray AR. Antigenic variation in a strain of *Trypanosoma brucei* transmitted by *Glossina morsitans* and *G. palpalis*. *J Gen Microbiol.* 1965;41(2):195-214. Epub 1965/11/01. doi: 10.1099/00221287-41-2-195. PubMed PMID: 5866129.
- Rojas F, Silvester E, Young J, Milne R, Tettey M, Houston DR, et al. Oligopeptide signaling through TbGPR89 drives trypanosome quorum sensing. *Cell.* 2018. Epub 2018/12/07. doi: 10.1016/j.cell.2018.10.041. PubMed PMID: 30503212.
- Vickerman K. Polymorphism and mitochondrial activity in sleeping sickness trypanosomes. *Nature.* 1965;208(5012):762-6. Epub 1965/11/20. PubMed PMID: 5868887.

5. Mantilla BS, Marchese L, Casas-Sanchez A, Dyer NA, Ejeh N, Biran M, et al. Proline metabolism is essential for *Trypanosoma brucei brucei* survival in the Tsetse Vector. PLoS pathogens. 2017;13(1):e1006158. doi: 10.1371/journal.ppat.1006158. PubMed PMID: 28114403.
6. Mowatt MR, Clayton CE. Developmental regulation of a novel repetitive protein of *Trypanosoma brucei*. Mol Cell Biol. 1987;7:2838-44.
7. Richardson JP, Beecroft RP, Tolson DL, Liu MK, Pearson TW. Procyclin: an unusual immunodominant glycoprotein surface antigen from the procyclic stage of African trypanosomes. Mol Biochem Parasit. 1988;31:203-16.
8. Rotureau B, Van Den Abbeele J. Through the dark continent: African trypanosome development in the tsetse fly. Front Cell Infect Microbiol. 2013;3:53. Epub 2013/09/26. doi: 10.3389/fcimb.2013.00053. PubMed PMID: 24066283; PubMed Central PMCID: PMC3776139.
9. Savage AF, Kolev NG, Franklin JB, Vigneron A, Aksoy S, Tschudi C. Transcriptome profiling of *Trypanosoma brucei* development in the Tsetse fly vector *Glossina morsitans*. PLoS One. 2016;11(12):e0168877. Epub 2016/12/22. doi: 10.1371/journal.pone.0168877. PubMed PMID: 28002435; PubMed Central PMCID: PMCPmc5176191.
10. Vigneron A, O'Neill MB, Weiss BL, Savage AF, Campbell OC, Kamhawi S, et al. Single-cell RNA sequencing of *Trypanosoma brucei* from tsetse salivary glands unveils metacyclogenesis and identifies potential transmission blocking antigens. Proceedings of the National Academy of Sciences of the United States of America. 2020;117:2613-21. Epub 2020/01/23. doi: 10.1073/pnas.1914423117. PubMed PMID: 31964820.
11. Siegel T, Hekstra D, Wang X, Dewell S, Cross G. Genome-wide analysis of mRNA abundance in two life-cycle stages of *Trypanosoma brucei* and identification of splicing and polyadenylation sites. Nucleic acids research. 2010;38:4946-57.
12. Gunasekera K, Wuthrich D, Braga-Lagache S, Heller M, Ochsenreiter T. Proteome remodelling during development from blood to insect-form *Trypanosoma brucei* quantified by SILAC and mass spectrometry. BMC genomics. 2012;13:556. Epub 2012/10/17. doi: 10.1186/1471-2164-13-556. PubMed PMID: 23067041; PubMed Central PMCID: PMC3545838.
13. Dejung M, Subota I, Bucerius F, Dindar G, Freiwald A, Engstler M, et al. Quantitative proteomics uncovers novel factors involved in developmental differentiation of *Trypanosoma brucei*. PLoS pathogens. 2016;12(2):e1005439. Epub 2016/02/26. doi: 10.1371/journal.ppat.1005439. PubMed PMID: 26910529; PubMed Central PMCID: PMCPmc4765897.
14. Jensen BC, Ramasamy G, Vasconcelos EJ, Ingolia NT, Myler PJ, Parsons M. Extensive stage-regulation of translation revealed by ribosome profiling of *Trypanosoma brucei*. BMC genomics. 2014;15:911. Epub 2014/10/22. doi: 10.1186/1471-2164-15-911. PubMed PMID: 25331479; PubMed Central PMCID: PMCPmc4210626.
15. Fadda A, Ryten M, Droll D, Rojas F, Färber V, Haanstra J, et al. Transcriptome-wide analysis of mRNA decay reveals complex degradation kinetics and suggests a role for co-transcriptional degradation in determining mRNA levels. Molecular microbiology. 2014;94:307-26. doi: 10.1111/mmi.12764. PubMed Central PMCID: PMCdoi: .
16. Antwi E, Haanstra J, Ramasamy G, Jensen B, Droll D, Rojas F, et al. Integrative analysis of the *Trypanosoma brucei* gene expression cascade predicts differential regulation of mRNA processing and unusual control of ribosomal protein expression. BMC genomics. 2016;17:306. doi: 10.1186/s12864-016-2624-3.
17. Vasquez JJ, Hon CC, Vanselow JT, Schlosser A, Siegel TN. Comparative ribosome profiling reveals extensive translational complexity in different *Trypanosoma brucei* life cycle

- stages. Nucleic acids research. 2014;42:3623-37. Epub 2014/01/21. doi: 10.1093/nar/gkt1386. PubMed PMID: 24442674; PubMed Central PMCID: PMCdoi: 10.1093/nar/gkt1386.
18. Brun R, Schonenberger M. Stimulating effect of citrate and cis-Aconitate on the transformation of *Trypanosoma brucei* bloodstream forms to procyclic forms in vitro. Z Parasitenkd. 1981;66(1):17-24. Epub 1981/01/01. PubMed PMID: 7324539.
19. Czichos J, Nonnengaesser C, Overath P. *Trypanosoma brucei*: cis-aconitate and temperature reduction as triggers of synchronous transformation of bloodstream to procyclic trypomastigotes in vitro. Exp Parasitol. 1986;62(2):283-91. Epub 1986/10/01. PubMed PMID: 3743718.
20. Opperdoes FR, Borst P. Localization of nine glycolytic enzymes in a microbody-like organelle in *Trypanosoma brucei*: the glycosome. FEBS Lett. 1977;80(2):360-4. Epub 1977/08/15. doi: 10.1016/0014-5793(77)80476-6. PubMed PMID: 142663.
21. Allmann S, Bringaard F. Glycosomes: A comprehensive view of their metabolic roles in *T. brucei*. The International Journal of Biochemistry & Cell Biology. 2018;85:85-90. doi: 10.1016/j.biocel.2017.01.015.
22. Osinga KA, Swinkels BW, Gibson WC, Borst P, Veeneman GH, Van Boom JH, et al. Topogenesis of microbody enzymes: a sequence comparison of the genes for the glycosomal (microbody) and cytosolic phosphoglycerate kinases of *Trypanosoma brucei*. Embo j. 1985;4(13b):3811-7. Epub 1985/12/30. PubMed PMID: 3004970; PubMed Central PMCID: PMCPMC554735.
23. Misset O, Opperdoes FR. Simultaneous purification of hexokinase, class-I fructose-bisphosphate aldolase, triosephosphate isomerase and phosphoglycerate kinase from *Trypanosoma brucei*. Eur J Biochem. 1984;144(3):475-83. Epub 1984/11/02. doi: 10.1111/j.1432-1033.1984.tb08490.x. PubMed PMID: 6489338.
24. Misset O, Opperdoes FR. The phosphoglycerate kinases from *Trypanosoma brucei*. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin. Eur J Biochem. 1987;162(3):493-500. Epub 1987/02/02. doi: 10.1111/j.1432-1033.1987.tb10667.x. PubMed PMID: 3830152.
25. Alexander K, Parsons M. Characterization of a divergent glycosomal microbody phosphoglycerate kinase from *Trypanosoma brucei*. Mol Biochem Parasitol. 1993;60:265-72.
26. Alexander K, Parsons M. A phosphoglycerate kinase-like molecule localized to glycosomal microbodies: evidence that the topogenic signal is not at the C-terminus. Mol Biochem Parasitol. 1991;46:1-10.
27. Aman RA, Wang CC. An improved purification of glycosomes from the procyclic trypomastigotes of *Trypanosoma brucei*. Mol Biochem Parasitol. 1986;21:211-20.
28. Hart DT, Misset O, Edwards SW, Opperdoes FR. A comparison of the glycosomes (microbodies) isolated from *Trypanosoma brucei* bloodstream form and cultured procyclic trypomastigotes. Mol Biochem Parasitol. 1984;12(1):25-35. Epub 1984/05/01. doi: 10.1016/0166-6851(84)90041-0. PubMed PMID: 6749187.
29. Blattner J, Helfert S, Michels P, Clayton CE. Compartmentation of phosphoglycerate kinase in *Trypanosoma brucei* plays a critical role in parasite energy metabolism. Proc Natl Acad Sci USA. 1998;95:11596-600.
30. Bakker BM, Mensonides FIC, Teusink B, van Hoek P, Michels PAM, Westerhoff HV. Compartmentation protects trypanosomes from the dangerous design of glycolysis. Proc Natl Acad Sci USA. 2000;97:2087-92.

31. Albert M-A, Haanstra J, Hannaert V, Van Roy J, Opperdoes F, Bakker B, et al. Experimental and in silico analyses of glycolytic flux control in bloodstream form *Trypanosoma brucei*. J Biol Chem. 2005;280:28306–15.
32. Deramchia K, Morand P, Biran M, Millerioux Y, Mazet M, Wagnies M, et al. Contribution of pyruvate phosphate dikinase in the maintenance of the glycosomal ATP/ADP balance in the *Trypanosoma brucei* procyclic form. J Biol Chem. 2014;289(25):17365-78. Epub 2014/05/06. doi: 10.1074/jbc.M114.567230. PubMed PMID: 24794874; PubMed Central PMCID: PMC4067170.
33. Clayton C, Michaeli S. 3' processing in protists. Wiley interdisciplinary reviews RNA. 2011;2:247-55. PubMed Central PMCID: PMC31957009
34. Michaeli S. Trans-splicing in trypanosomes: machinery and its impact on the parasite transcriptome. Future Microbiol. 2011;6(4):459-74. Epub 2011/04/30. doi: 10.2217/fmb.11.20. PubMed PMID: 21526946.
35. Gibson WC, Swinkels BW, Borst P. Post-transcriptional control of the differential expression of phosphoglycerate kinase genes in *Trypanosoma brucei*. J Mol Biol. 1988;201:315-25.
36. Kolev N, Franklin J, Carmi S, Shi H, Michaeli S, Tschudi C. The transcriptome of the human pathogen *Trypanosoma brucei* at single-nucleotide resolution. PLoS pathogens. 2010;6:e1001090.
37. Clayton C. Control of gene expression in trypanosomatids: living with polycistronic transcription. Royal Society Open Biology. 2019;9:190072. doi: 10.1098/rsob.190072. PubMed Central PMCID: PMC6597758.
38. Rico-Jiménez M, Ceballos-Pérez G, Gómez-Liñán C, Estévez AM. An RNA-binding protein complex regulates the purine-dependent expression of a nucleobase transporter in trypanosomes. Nucleic acids research. 2021;49(7):3814-25. Epub 2021/03/22. doi: 10.1093/nar/gkab181. PubMed PMID: 33744953; PubMed Central PMCID: PMC8053114.
39. Wurst M, Selinger B, Jha B, Klein C, Queiroz R, Clayton C. Expression of the RNA Recognition Motif protein RBP10 promotes a bloodstream-form transcript pattern in *Trypanosoma brucei*. Molecular microbiology. 2012;83:1048-63. doi: 10.1111/j.1365-2958.2012.07988.x. PubMed Central PMCID: PMC22296558.
40. Christiano R, Kolev N, Shi H, Ullu E, Walther T, Tschudi C. The proteome and transcriptome of the infectious metacyclic form of *Trypanosoma brucei* define quiescent cells primed for mammalian invasion. Molecular microbiology. 2017;106:74-92. PubMed Central PMCID: PMC10.1111/mmi.13754.
41. Shi H, Butler K, Tschudi C. Differential expression analysis of transcriptome data of *Trypanosoma brucei* RBP6 induction in procyclics leading to infectious metacyclics and bloodstream forms in vitro. Data Brief. 2018;20:978-80. Epub 2018/09/19. doi: 10.1016/j.dib.2018.08.169. PubMed PMID: 30225310; PubMed Central PMCID: PMC6139001.
42. Silvester E, Ivens A, Matthews KR. A gene expression comparison of *Trypanosoma brucei* and *Trypanosoma congolense* in the bloodstream of the mammalian host reveals species-specific adaptations to density-dependent development. PLoS neglected tropical diseases. 2018;12(10):e0006863. Epub 2018/10/12. doi: 10.1371/journal.pntd.0006863. PubMed PMID: 30307943; PubMed Central PMCID: PMC6199001.
43. Qiu Y, Milanes JE, Jones JA, Noorai RE, Shankar V, Morris JC. Glucose Signaling Is Important for Nutrient Adaptation during Differentiation of Pleomorphic African Trypanosomes.

mSphere. 2018;3(5):e00366-18. Epub 2018/11/02. doi: 10.1128/mSphere.00366-18. PubMed PMID: 30381351; PubMed Central PMCID: PMC6211221.

44. Naguleswaran A, Doiron N, Roditi I. RNA-Seq analysis validates the use of culture-derived *Trypanosoma brucei* and provides new markers for mammalian and insect life-cycle stages. BMC genomics. 2018;19(1):227. Epub 2018/04/03. doi: 10.1186/s12864-018-4600-6. PubMed PMID: 29606092; PubMed Central PMCID: PMC5879877.

45. Queiroz R, Benz C, Fellenberg K, V S, Hoheisel J, Clayton C. Transcriptome analysis of differentiating trypanosomes reveals the existence of multiple post-transcriptional regulons. BMC genomics. 2009;10:495.

46. Toh JY, Nkouawa A, Sánchez SR, Shi H, Kolev NG, Tschudi C. Identification of positive and negative regulators in the stepwise developmental progression towards infectivity in *Trypanosoma brucei*. Scientific reports. 2021;11(1):5755. Epub 2021/03/13. doi: 10.1038/s41598-021-85225-2. PubMed PMID: 33707699; PubMed Central PMCID: PMC7952579.

47. Doleželová E, Kunzová M, Dejung M, Levin M, Panicucci B, Regnault C, et al. Cell-based and multi-omics profiling reveals dynamic metabolic repurposing of mitochondria to drive developmental progression of *Trypanosoma brucei*. PLoS Biol. 2020;18(6):e3000741. Epub 2020/06/11. doi: 10.1371/journal.pbio.3000741. PubMed PMID: 32520929; PubMed Central PMCID: PMC7307792.

48. Urbaniak MD, Guthrie ML, Ferguson MA. Comparative SILAC proteomic analysis of *Trypanosoma brucei* bloodstream and procyclic lifecycle stages. PLoS One. 2012;7(5):e36619. Epub 2012/05/11. doi: 10.1371/journal.pone.0036619. PubMed PMID: 22574199; PubMed Central PMCID: PMC3344917.

49. Mugo E, Clayton C. Expression of the RNA-binding protein RBP10 promotes the bloodstream-form differentiation state in *Trypanosoma brucei*. PLoS pathogens. 2017;13:e1006560. doi: 10.1371/journal.ppat.1006560. PubMed Central PMCID: PMC5568443 PMID: 2880058.

50. Mugo E, Egler F, Clayton C. Conversion of procyclic-form *Trypanosoma brucei* to the bloodstream form by transient expression of RBP10. Molecular and biochemical parasitology. 2017;216C:49-51. doi: 10.1016/j.molbiopara.2017.06.009.

51. Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Gerstein M, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008;320(5881):1344-9. Epub 2008/05/03. doi: 10.1126/science.1158441. PubMed PMID: 18451266; PubMed Central PMCID: PMC2951732.

52. Jan CH, Friedman RC, Ruby JG, Bartel DP. Formation, regulation and evolution of *Caenorhabditis elegans* 3'UTRs. Nature. 2011;469(7328):97-101. Epub 2010/11/19. doi: 10.1038/nature09616. PubMed PMID: 21085120; PubMed Central PMCID: PMC3057491.

53. Liu B, Marucha K, Clayton C. The zinc finger proteins ZC3H20 and ZC3H21 stabilise mRNAs encoding membrane proteins and mitochondrial proteins in insect-form *Trypanosoma brucei* Molecular microbiology. 2020;113:430-51. doi: 10.1111/mmi.14429.

54. Melo do Nascimento L, Egler F, Arnold K, Papavasilou N, Clayton C, Erben E. Functional insights from a surface antigen mRNA-bound proteome. eLife. 2021;10:e68136. doi: <https://doi.org/10.7554/eLife.68136>.

55. Colasante C, Robles A, Li C-H, Schwede A, Benz C, Voncken F, et al. Regulated expression of glycosomal phosphoglycerate kinase in *Trypanosoma brucei*. Mol Biochem Parasitol. 2007;151:193-204.

56. Khong A, Parker R. The landscape of eukaryotic mRNPs. *RNA* (New York, NY). 2020;26(3):229-39. Epub 2019/12/28. doi: 10.1261/rna.073601.119. PubMed PMID: 31879280.
57. Benz C, Mulindwa J, Ouna B, Clayton C. The *Trypanosoma brucei* zinc finger protein ZC3H18 is involved in differentiation. *Molecular and biochemical parasitology*. 2011;177:148-51. doi: DOI: 10.1016/j.molbiopara.2011.02.007. PubMed Central PMCID: PMCPMID: 21354218
58. Clayton CE, Estévez AM, Hartmann C, Alibu VP, Field M, Horn D. Down-regulating gene expression by RNA interference in *Trypanosoma brucei*. In: Carmichael. G, editor. *RNA interference. Methods in Molecular Biology*; Humana Press; 2005.
59. Vassella E, Kramer R, Turner CM, Wankell M, Modes C, van den Bogaard M, et al. Deletion of a novel protein kinase with PX and FYVE-related domains increases the rate of differentiation of *Trypanosoma brucei*. *Molecular microbiology*. 2001;41(1):33-46. Epub 2001/07/17. PubMed PMID: 11454198.
60. Blattner J, Clayton CE. The 3'-untranslated regions from the *Trypanosoma brucei* phosphoglycerate kinase genes mediate developmental regulation. *Gene*. 1995;162:153-6.
61. Mulindwa J, Leiss K, Ibberson D, Kamanyi Marucha K, Helbig C, Melo do Nascimento L, et al. Transcriptomes of *Trypanosoma brucei rhodesiense* from sleeping sickness patients, rodents and culture: Effects of strain, growth conditions and RNA preparation methods. *PLoS neglected tropical diseases*. 2018;12(2):e0006280. Epub 2018/02/24. doi: 10.1371/journal.pntd.0006280. PubMed PMID: 29474390; PubMed Central PMCID: PMCPMC5842037.
62. Li C-H, Irmer H, Gudjonsdottir-Planck D, Freese S, Salm H, Haile S, et al. Roles of a *Trypanosoma brucei* 5'->3' exoribonuclease homologue in mRNA degradation. *RNA* (New York, NY). 2006;12:2171-86. doi: 10.1261/rna.291506. PubMed Central PMCID: PMCPMID: 17077271 PMCID: PMC1664730 DOI: .
63. Müller L, Cosentino R, Förstner K, Guizetti J, Wedel C, Kaplan N, et al. Genome organization and DNA accessibility control antigenic variation in trypanosomes. *Nature*. 2018;563:121-5. doi: /10.1038/s41586-018-0619-8.
64. de Freitas Nascimento J, Kelly S, Sunter J, Carrington M. Codon choice directs constitutive mRNA levels in trypanosomes. *eLife*. 2018;7:e32467. Epub 2018/03/16. doi: 10.7554/eLife.32467. PubMed PMID: 29543152; PubMed Central PMCID: PMCPMC5896880.
65. Jeacock L, Faria J, Horn D. Codon usage bias controls mRNA and protein abundance in trypanosomatids. *eLife*. 2018;7. Epub 2018/03/16. doi: 10.7554/eLife.32496. PubMed PMID: 29543155; PubMed Central PMCID: PMCPMC5896881.
66. Bailey T. DREME: Motif discovery in transcription factor ChIP-seq data. *Bioinformatics*. 2011;27:1653-9.
67. Bailey T, Johnson J, Grant C, Noble W. The MEME Suite. *Nucleic acids research*. 2015;43:W39-W49.
68. Hotz H-R, Lorenz P, Fischer R, Krieger S, Clayton CE. Developmental regulation of hexose transporter mRNAs in *Trypanosoma brucei*. *Mol Biochem Parasitol*. 1995;75:1-14.
69. Webb H, Burns R, Kimblin N, Ellis L, Carrington M. A novel strategy to identify the location of necessary and sufficient cis-acting regulatory mRNA elements in trypanosomes. *RNA* (New York, NY). 2005;11(7):1108-16. Epub 2005/06/02. doi: 10.1261/rna.2510505. PubMed PMID: 15928343; PubMed Central PMCID: PMCPMC1360220.

FIGURE LEGENDS

Figure 1. Developmental regulation of the *RBP10* mRNA.

A. RNA-sequencing data and ribosome profiling [14] reads for bloodstream forms (B) and procyclic forms (P), aligned to the relevant segment of the TREU927 reference genome. Unique reads are in blue and non-unique reads are in grey, on a log scale. The sequences in the *RBP10* (Tb927.8.2780) 3'-UTR designated as non-unique in this image are also present in an TREU927 DNA contiguous sequence that has not been assigned to a specific chromosome; this segment is absent in the Lister427 (2018) genome. The positions of open reading frames (black) and untranslated regions have been re-drawn, with the initial "Tb927.8" removed for simplicity. Transcription is from left to right.

Data from all remaining panels are for the EATRO1125 strain.

B. Northern blot for two independent cultures showing the relative mRNA abundance of *RBP10* mRNA in bloodstream forms and in procyclic forms. A section of methylene blue staining is depicted to show the loading and the measured amounts in procyclic forms, relative to bloodstream forms, are also shown.

C. Regulation of *RBP10* protein expression during differentiation. Cells were incubated with or without 6 mM *cis*-aconitate at the temperatures and for the times indicated. The asterisk shows a band that cross-reacts with the antibody, and was used as a control. The graph shows quantitation from three independent experiments.

D. Half-life of *RBP10* mRNA. Cells were incubated with Actinomycin D (10 µg/ml) and Sinefungin (2 µg/ml) to stop both mRNA processing and transcription. The amount of *RBP10* mRNA in bloodstream forms was measured in three independent replicates. The initial delay or even increase in abundance is commonly seen for relatively stable trypanosome mRNAs, and is of unknown origin.

E. The *RBP10* 3'-UTR is sufficient for regulation. A dicistronic construct mediating puromycin resistance (*PAC* gene) and encoding chloramphenicol acetyltransferase (*CAT* gene) replaced one of the two *RBP10* open reading frames (upper panel) in bloodstream forms. These then were differentiated to procyclic forms. The lower panel shows measurements of *CAT* activity and mRNA for three independent cell lines, normalised to the average for bloodstream forms.

Figure 2. The *RBP10* 3'-UTR contains several regulatory sequences.

A. Cartoon showing the *CAT* reporter construct (pHD2164) used in this study. The different fragments of the *RBP10* 3'-UTR were cloned downstream of the *CAT* reporter coding sequence. The polyadenylation site "p(A)" is specified by the *NPT* splice signal. *SL* indicates the spliced leader addition sites. *ACT* denotes actin.

B. Schematic diagram of the *RBP10* 3'-UTR segments used to map the regulatory sequences. Measurements of *CAT* activity and mRNA levels are on the right. Each dot is a result for an independent clone, with blue and red representing bloodstream (B) and procyclic (P) forms, respectively. Values were normalized to those for the *ACT* 3'-UTR control (pHD2164). The average result for the control BSF cell line

was set to 1. For "expression", averages are: "-" = <0.25x, "+/-" = 0.25-0.5x, "+" = 0.5-2x, "++"=2-3x and "+++" >3x.

Figure 3. The *PGKC* 3'-UTR contains at least two regulatory sequences.

A. Cartoon showing one of the *CFP* reporter constructs (pHD3261) used in this study. Different fragments of the *PGKC* 3'-UTR were cloned downstream of the *CFP* reporter coding sequence. The polyadenylation site "p(A)" is specified by the *PAC* splice signal. *TUB* denotes the tubulin locus. *ACT* denotes actin.

B. Schematic diagram of the *PGKC* 3'-UTR segments used to map the regulatory sequences. Measurements are on the right. Each dot is a result for an independent clone, with blue and red representing bloodstream (B) and procyclic (P) forms, respectively. Protein levels were estimated from Western blot quantitation and mRNA levels were measured by real-time PCR, taking the average of three technical replicates for at least two independent clones. Values were normalized to the arithmetic mean for the *PGKC* 3'-UTR control clones, bloodstream forms with pHD3261. For "expression", averages are: "-" = <0.25x, "+/-" = 0.25-0.5x, "+" = 0.5-2x, "++"=2-3x and "+++" >3x.

C. RNA from the bloodstream-form samples used in (B) were examined on Northern blots to examine the size of *CFP* mRNAs bearing *PGKC* 3'-UTRs. The methylene blue-stained membrane and the tubulin mRNAs are shown as loading controls.

Figure 4. Analysis of specific sequences.

A. Results for a *CAT* reporter plasmid containing *RBP10* 3'-UTR fragment 1.2 bearing (AU)₁₀ repeats and a mutated version without them. The average result for the fragment with the repeats is set to 1.

B. As (A) but showing deletion of a poly(A) tract from fragment 3.1.1.

C. Results for a *CFP* reporter plasmid containing the *ACT* 3'-UTR with either (AT)₁₀ or the *PGKC** fragment inserted after the *CFP* coding region.

Figure 5. Model for developmental regulation of *RBP10* and *PGKC*.

The two mRNAs are shown approximately to scale, using the colour coding from Figures 2 and 3. Regulatory RNA-binding proteins that bind the the 3'-UTRs are shown schematically with different shapes; it is possible that some of them bind in more than one position. Proteins that bind but do not give strong regulation, or which compete with other proteins for binding, are almost certainly also present but are not indicated.

Supplements.

S1 Table. Plasmids and oligonucleotides.

S2 Table. mRNA lengths.

713 **S1 Fig. *PGKC* 3'-UTR sequence alignments.**

714 The sequences were aligned using the Segman programme in the DNASTar package.

715 **S1 Text. *RBP10* 3'-UTR sequences.**

716 **S2 Text. *PGKC* 3'-UTR sequence.**

717 **S1 file. pHD3261 sequence in ApE format.**

718 **S2 file. pHD3301 sequence in ApE format.**

719

720

Figure 1

Figure 3

Figure 4

Figure 2

Figure 5